This is a prospective, multicenter, non-inferior, parallel-controlled observational study. This study aims to compare clinical outcomes of endovascular treatment for acute high-risk type B aortic dissection in the acute phase versus the subacute phase. No interventions will be imposed on the patients' standard treatment. Patients with acute high-risk type B aortic dissection will be grouped based on the actual timing of their treatment.
Study Type
OBSERVATIONAL
Enrollment
4,068
Patients with acute high-risk type B aortic dissection received endovascular treatment in acute phase (2-14days)
Patients with acute high-risk type B aortic dissection received endovascular treatment in subacute phase (≥14days)
Shanghai Zhongshan Hospital
Shanghai, China
30-day all-cause mortality rate
paraplegia, stroke, new entry tear, renal/liver dysfunction, type I/II/R endoleak
Time frame: 30 days following the operation
30-day complication rate
access site complications
Time frame: 30 days following the operation
Adverse events
rupture, stent-induced new entry, ischemia (renal/limb/intestinal/spinal), endoleak, dissection aneurysm, stroke, venous thrombosis, all-cause death.
Time frame: 12 months following the operation
aortic remodeling
aortic diameter growth \> 5 mm in 12 months; dissection aneurysm
Time frame: 12 months following the operation
5-year all-cause mortality rate
long-term outcome
Time frame: 5 years following the operation
5-year complication rate
long-term outcome
Time frame: 5 years following the operation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.